Statement - Rx&D Applauds Efforts of Canadian Cancer Society to Provide
Patients with Improved Access to Life-Saving New Medicines
"Canada's Research-Based Pharmaceutical Companies commends the Canadian Cancer Society for exposing the huge gaps across
"The Society's report "Cancer Drug Access for Canadians" illustrates that patients are not well served by the discrepancy in access to new medicines between provincial programs. Canadians who rely on public drug plans have access to only about one in five of the new medicines that are approved by Health
"As the industry that discovers medicines that improve and save lives, we agree with the principle that Canadians should have access to the most appropriate drug to treat their condition regardless of where they live or their income level.
"It is difficult enough for patients and their families who are diagnosed with a life threatening disease. They should not be forced to fight for access to the medicine they need because it isn't covered under a provincial drug plan.
"An estimated 1 out of every 4 Canadian is expected to die from cancer, which is the leading cause of premature death in
"Patients must come first. Our industry's commitment is to work in partnership with governments and other stakeholders to develop a plan that supports research and innovation while promoting access to new medicines for those who are stricken with catastrophic illness."
About Rx&D
Rx&D is an association of leading research-based pharmaceutical companies dedicated to improving the health of all Canadians through the discovery and development of new medicines and vaccines. Our community represents 20,000 men and women working for 50 member companies and invests more than
For further information: François Lessard, Communications, Telephone: (613) 236-0455, E-mail: [email protected]
Share this article